Loading...
Ibrutinib is an oral, covalent inhibitor of Bruton's tyrosine kinase, a mediator of B-cell receptor signaling implicated in lymphomagenesis. Mantle-cell lymphoma (MCL) is an aggressive tumor that often relapses after initial responses to chemotherapy. Is there a role for ibrutinib in patients with refractory or relapsed MCL?
To find out, investigators conducted an industry-funded, multicenter, phase II trial in which 111 previously treated MCL patients received ibrutinib (560 mg per day). Results were as follows:
Ibrutinib was well tolerated; most adverse events (diarrhea in 50%, fatigue in 41%) were low grade. Grade 3 and 4 hematologic toxicity included neutropenia (16%), thrombocytopenia (11%), and anemia (10%).
Grade 3 infections occurred i…